Olivier Loeillot - 21 Apr 2026 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RGEN
Reported as of: 21 Apr 2026
Net transaction value: -$536,480
SEC form: 4
Accepted by SEC: 22 Apr 2026, 13:26:04 UTC
Prior SEC filing: 23 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Carmichael (Attorney in Fact)

Key filing fact

Olivier Loeillot filed Form 4 for REPLIGEN CORP (RGEN) on 22 Apr 2026.

Key facts

This page summarizes Olivier Loeillot's Form 4 filing for REPLIGEN CORP (RGEN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Apr 2026, 13:26.

Change

Previous filing in this sequence was filed on 23 Mar 2026.
Current net transaction value: -$536,480.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001995525 Primary reporting owner

Loeillot Olivier

Relationship: Chief Executive Officer, Director
Address: C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM
Signature: /s/ Jennifer Carmichael (Attorney in Fact)
Signature date: 22 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGEN transaction

Common Stock

Sale

Transaction value: $536,480
Shares: -3,832
Change %: -6.6%
Price: $140.00
Shares after: 54,246
Date: 21 Apr 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025.